Maiti Baidehi, Setrakian Sebouh, Daw Hamed A
Department of Internal Medicine, 18101 Lorain Avenue, Fairview Hospital, Cleveland, Ohio 44111, USA.
Cases J. 2009 May 26;2:7526. doi: 10.1186/1757-1626-2-7526.
Imatinib, a tyrosine kinase inhibitor has revolutionized the therapy of Philadelphia chromosome positive chronic myeloid leukemia. Side effects of imatinib include grade 1-4 hepatotoxicity in a subset of patients. We report the case of a 46-year-old male with chronic myeloid leukemia, who developed hepatic hemosiderosis during treatment with imatinib. After ruling out the established congenital and acquired causes of hepatic hemosiderosis, we attribute this to a possible side effect of imatinib therapy. This condition was successfully treated with periodic phlebotomy thus precluding discontinuation of imatinib. To our knowledge, this is the first report of hepatic hemosiderosis most likely consequent to imatinib therapy.
伊马替尼，一种酪氨酸激酶抑制剂，彻底改变了费城染色体阳性慢性髓性白血病的治疗方法。伊马替尼的副作用包括一部分患者出现1 - 4级肝毒性。我们报告了一例46岁慢性髓性白血病男性患者，他在接受伊马替尼治疗期间发生了肝铁沉积症。在排除已确定的先天性和后天性肝铁沉积症病因后，我们将其归因于伊马替尼治疗可能产生的副作用。通过定期放血成功治疗了这种情况，从而避免了停用伊马替尼。据我们所知，这是第一例很可能由伊马替尼治疗导致的肝铁沉积症报告。
